Harbor Investment Advisory LLC raised its holdings in Humana Inc. (NYSE:HUM – Get Rating) by 163.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 161 shares of the insurance provider's stock after buying an additional 100 shares during the quarter. Harbor Investment Advisory LLC's holdings in Humana were worth $75,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC purchased a new stake in Humana in the 2nd quarter valued at about $1,555,000. Veriti Management LLC grew its holdings in shares of Humana by 3.7% during the 2nd quarter. Veriti Management LLC now owns 3,200 shares of the insurance provider's stock worth $1,498,000 after purchasing an additional 114 shares during the period. Global Retirement Partners LLC grew its holdings in shares of Humana by 29.7% during the 2nd quarter. Global Retirement Partners LLC now owns 205 shares of the insurance provider's stock worth $96,000 after purchasing an additional 47 shares during the period. Newbridge Financial Services Group Inc. grew its holdings in shares of Humana by 42.3% during the 2nd quarter. Newbridge Financial Services Group Inc. now owns 74 shares of the insurance provider's stock worth $35,000 after purchasing an additional 22 shares during the period. Finally, HB Wealth Management LLC grew its holdings in shares of Humana by 16.0% during the 2nd quarter. HB Wealth Management LLC now owns 2,784 shares of the insurance provider's stock worth $1,303,000 after purchasing an additional 385 shares during the period. Hedge funds and other institutional investors own 93.50% of the company's stock.
Get
Humana alerts:
Insider Activity
In other news, insider Joseph C. Ventura sold 1,226 shares of the business's stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $506.78, for a total value of $621,312.28. Following the completion of the sale, the insider now directly owns 3,930 shares in the company, valued at approximately $1,991,645.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.39% of the company's stock.
Humana Stock Performance
Shares of HUM opened at $487.31 on Wednesday. The business's 50 day moving average is $487.46 and its two-hundred day moving average is $462.42. Humana Inc. has a 52-week low of $351.20 and a 52-week high of $514.98. The firm has a market cap of $61.67 billion, a price-to-earnings ratio of 19.89, a PEG ratio of 1.41 and a beta of 0.77. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.73.
Humana (NYSE:HUM – Get Rating) last announced its earnings results on Wednesday, July 27th. The insurance provider reported $8.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $7.67 by $1.00. Humana had a return on equity of 18.42% and a net margin of 3.52%. The company had revenue of $23.66 billion for the quarter, compared to analyst estimates of $23.44 billion. During the same period in the prior year, the company posted $6.89 EPS. Humana's quarterly revenue was up 14.6% on a year-over-year basis. Analysts forecast that Humana Inc. will post 25 EPS for the current fiscal year.
Humana Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Shareholders of record on Friday, September 30th will be given a $0.7875 dividend. This represents a $3.15 dividend on an annualized basis and a dividend yield of 0.65%. The ex-dividend date of this dividend is Thursday, September 29th. Humana's payout ratio is 12.86%.
Analysts Set New Price Targets
A number of analysts have recently issued reports on HUM shares. SVB Leerink boosted their target price on Humana from $535.00 to $540.00 and gave the stock an "outperform" rating in a report on Thursday, July 28th. Oppenheimer boosted their target price on Humana from $520.00 to $550.00 and gave the stock an "outperform" rating in a report on Friday, September 16th. Credit Suisse Group set a $548.00 target price on Humana in a report on Tuesday, July 19th. Cowen boosted their target price on Humana to $547.00 in a report on Tuesday, August 9th. Finally, StockNews.com lowered Humana from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 29th. Four research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to MarketBeat, Humana has an average rating of "Moderate Buy" and an average target price of $519.28.
Humana Company Profile
(Get Rating)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
See Also
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM – Get Rating).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
